Global Multi-Omics Market is set to be driven by high demands for Personalized Medicine and Technological Advancements

Omics has turned out to be a new mantra in molecular research. It is a field of study in biological sciences that ends in the suffix – omics. Many areas of research can be classified as omics such as genomics, transcriptomics, proteomics and metabolomics.

·        Genomics studies genes and their function. Genomics finds application in drug discovery and development, diagnostics & therapeutic decision-making, agriculture, animal research and other applications.

·        Transcriptomics studies mRNAs. It is widely used for clinical diagnostics, drug discovery, toxicogenomics and other applications.

·        Proteomics studies proteins. It is used for clinical diagnosis of cancer, infectious diseases, cardiovascular diseases, immune diseases, neurological disorders, diabetes, etc. and drug discovery.

·        Metabonomics studies small molecules involved in cellular metabolism. It is a powerful research tool that is currently being applied to various aspects of drug and biomarker discovery, toxicology research, nutrigenomics and other applications

Complete understanding of human health and diseases warrants interpretation of molecular intricacy and variations at multiple levels such as genome, transcriptome, proteome, and metabolome. With the advent of sequencing technology, biology has become increasingly reliant on data generated at these levels, which collectively is called as “Multi-Omics” data. Availability of Multi-Omics market data has revolutionized the field of medicine and biology. Data integration across different platforms (genomics, transcriptomics, proteomics and metabolomics) helps in understanding causal relationships across multiple levels of cellular organization in the Multi-Omics market. It offers unparalleled opportunities to understand the underlying biology of complex diseases such as cancer.

Competitive Landscape Analysis : Multi-Omics Market

Some of the key players operating in the Global Multi-Omics market are 10x Genomics, Bio-Techne Corporation, Fluidigm Corporation, Bio-Rad Laboratories, Inc., NanoString, Mission Bio, BD Biosciences, Thermo Fisher Scientific Inc., among others.

Single-Cell Analysis Enters the Era of Multi-Omics Market

A cell's condition can be defined by the interplay between its genome, epigenome, transcriptome, and proteome. Riding on the development of these omics technologies, Multi-Omics technologies for single cells have emerged that are able to capture multiple omic layers from the same cell. Profiling multiple omic layers makes it possible to capture a more complete set of information about each cell than is possible from any single omic layer alone. Single-cell Multi-Omics better reflects the complex network of interactions that are responsible for cellular functions and hence are considered more powerful than a stand-alone omics.

For Your Customized Research Requirements, Contact Us @ https://meditechinsights.com/contact-us/

Comments

Post a Comment

Popular posts from this blog

Global HPV Testing and PAP Test Market is slated to grow at a lucrative CAGR of 12 to 15 % by 2027 – Growing Revolution for the Prevention of Cervical Cancer

Cervical cancer is a malignant tumor which starts in the cells of the cervix, the lowermost part of the uterus. Cervical cancer begins when the cells on its surface transforms into precancerous cells. If not destroyed, these abnormal cells may turn into harmful cancer cells and spread in the cervix and surrounding areas. Cervical cancer screening involves HPV and PAP tests , which can identify HPV infection or pre-cancerous lesions at an early stage and if correct treatment is offered at the right time then the cancer can be prevented. Impact of  Covid-19 on  the Global HPV Testing and PAP Test Market Covid-19 pandemic had impacted the healthcare market in many ways. During Covid pandemic, due to strict social-distancing norms in hospitals, there was a delay in many diagnostic examinations and procedures. The delay in the cancer screening services due to the lack of skilled healthcare staff and disruption in the supply chain of testing kits across the world had led to a severe impact o
Read more

Global Ambulatory Surgical Center (ASC) Software Market is Poised to Grow at a CAGR of 10% by 2027

Ambulatory Surgical Care is a medical care offered in the outpatient setting and does not need any hospital admission. Ambulatory Surgical Center or ASCs—are health care facilities focused on offering same-day surgical care, including diagnostic and preventive procedures. ASCs have transformed the outpatient experience by offering a convenient alternative to hospital-based outpatient procedures. Common procedures performed in ASCs are cataract surgery, gallbladder removal, tonsillectomy, endoscopy, colonoscopy, arthroscopic or orthopedic procedures, and cardiac procedures. Owing to their various cost benefits and convenience, the volume of procedures performed at ASCs is rising and ASC software is likely to play a major role in these settings by easing the day to day operations by preparing staff and patients for pre-op and post-op tasks. Rising Investments in Ambulatory Surgical Center  from Healthcare Companies Shows a Huge Growth Potential for Ambulatory Surgical Center Software Ma
Read more

Global Drug Discovery Software market valued at $2 billion in 2020, is projected to grow at a healthy CAGR of 14% to reach $3.5 billion by 2025

The global drug discovery software market (such as ligand-based design, structure-based design, LIMS, ELN) is driven by the increasing R&D spend and pipeline, expanding scope and scale, increasing stringency of testing and regulations, growing number and size of biotechs, need for increasing cost efficiencies and reducing time to market, and move towards web/cloud-based software. Global Drug Discovery Software Market – Niche but Fast-Growing Market The worldwide drug discovery software market is niche and growing rapidly, driven by the rising pressure on the pharma and biotech companies to cut costs in the research and preclinical stage of drug development, reduce timelines and improve transparency through deep learning software tools. “ Large players present in this segment are trying to consolidate the market by becoming a one stop shop. Moreover, companies are also considering to combine their solutions with bioinformatics and LIMS tools to have a competitive edge .” - Exe
Read more